GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. (GEHC)
Overview
GE HealthCare is a global medical technology, pharmaceutical diagnostics, and digital solutions company that designs, manufactures, and services the equipment hospitals and clinicians use to diagnose and monitor patients. Headquartered in Chicago, Illinois, the company traces its roots back to X-ray equipment maker Victor Electric (founded 1893, acquired by General Electric in 1920) and became an independent, publicly traded company on January 4, 2023, when General Electric spun it off as part of GE's broader breakup into three focused companies. GE HealthCare employs about 54,000 people, operates in over 100 countries, and generated approximately $20.6 billion in revenue in fiscal 2025 (up roughly 5% year over year), with net income of about $2.1 billion. It trades on the Nasdaq under the ticker GEHC.
What They Do & How They Make Money
GE HealthCare makes money by selling capital medical equipment — such as CT scanners, MRI machines, X-ray systems, and ultrasound devices — to hospitals, imaging centers, and health systems, and then generating a long tail of recurring revenue from servicing, maintaining, and upgrading that equipment over its multi-year (often decade-plus) operating life. This product-plus-service model is reflected in the company's revenue split: roughly two-thirds of revenue comes from product sales (new equipment and consumables) and roughly one-third from services (maintenance contracts, software, and support), with services carrying higher margins and providing a stable, recurring revenue base once large capital equipment is installed in a hospital. The company also sells contrast agents and radiopharmaceutical diagnostic products that are used alongside its imaging equipment (and competitors' equipment) during scans, creating an additional consumables revenue stream tied to imaging procedure volumes. Increasingly, GE HealthCare is layering AI-enabled software and digital/data solutions — for example, through its DeepHealth collaboration — on top of its hardware base, aiming to improve diagnostic accuracy, workflow efficiency, and to create new subscription-like software revenue streams.
Business Segments
GE HealthCare reports four business segments:
- Imaging — The company's largest segment, manufacturing CT scanners, MR (MRI) systems, molecular imaging equipment, X-ray systems, and women's health imaging products. This segment sells the big-ticket diagnostic imaging hardware that hospitals rely on for most in-depth diagnostic procedures.
- Advanced Visualization Solutions (AVS) — Includes ultrasound systems, image-guided therapy devices, and interventional tools used in women's health, cardiovascular care, and surgical visualization.
- Patient Care Solutions (PCS) — Supplies patient monitoring devices, diagnostic cardiology equipment, anesthesia and respiratory care systems, maternal-infant care products, and related consumables and digital health tools used throughout a patient's hospital stay.
- Pharmaceutical Diagnostics (PDx) — Produces contrast media and radiopharmaceutical tracers administered to patients to improve the visibility and diagnostic value of CT, MR, and nuclear medicine scans; this is a consumables-driven, recurring-revenue business tied to imaging procedure volume across the industry (not just GE's own installed base).
Imaging is the largest revenue contributor by a meaningful margin, followed by AVS and Patient Care Solutions, with Pharmaceutical Diagnostics being the smallest of the four but a valuable high-margin, recurring consumables business.
Competitors
GE HealthCare operates in a concentrated, capital-intensive global medical device market:
- Diagnostic imaging (broad-line): Siemens Healthineers (Germany) and Koninklijke Philips (Netherlands) are GE HealthCare's closest full-line competitors, offering comparable ranges of CT, MRI, ultrasound, and X-ray systems.
- Imaging (Japan-based): Fujifilm Holdings (including its Fujifilm Healthcare/former Hitachi medical business) and Canon Medical Systems compete strongly in CT, MRI, and ultrasound, particularly in Asian markets.
- Patient monitoring: Philips and Medtronic, along with specialized monitoring companies, compete in the patient care/monitoring space.
- Pharmaceutical diagnostics: Bracco Imaging, Bayer's radiology division, and Lantheus Holdings compete in contrast agents and radiopharmaceuticals.
- Point-of-care and niche imaging: A range of smaller, specialized device makers compete in narrower categories such as portable ultrasound or specific monitoring niches.
Competitive Position
GE HealthCare benefits from a large, entrenched installed base of imaging and monitoring equipment across hospitals worldwide — the "GE" brand carries decades of trust with radiologists, clinicians, and hospital procurement departments, and switching to a competitor's imaging platform involves significant retraining, workflow disruption, and capital cost, creating meaningful customer stickiness. Its scale allows heavy, sustained investment in R&D (including AI-based diagnostic and workflow software) and a global service and support network that smaller competitors struggle to match. The company's diversified segment mix — spanning big-ticket capital equipment, everyday consumables (contrast agents), and recurring service contracts — provides some insulation against any single segment's cyclicality.
Key risks include intense competition from Siemens Healthineers and Philips, both of which are similarly scaled and investing heavily in AI-enabled imaging and software; pricing pressure from hospital systems and group purchasing organizations, especially in cost-constrained healthcare markets; and exposure to hospital capital spending cycles, which can slow during periods of economic uncertainty or healthcare system budget tightening. Supply chain constraints (as seen industry-wide in recent years) can also affect the availability of components for complex imaging systems. Regulatory risk is significant given the medical device and pharmaceutical nature of the business — new products require regulatory clearance (e.g., FDA, CE marking) in each market, and quality or safety issues can trigger recalls or reputational damage. Longer term, the shift toward AI-driven diagnostics and value-based care creates both an opportunity (higher-margin software and data services) and a risk (new AI-native entrants or software-only competitors eroding the value of pure hardware differentiation). Overall, GE HealthCare holds a leading, durable position as one of the top two or three players in most of its major imaging and monitoring categories globally.